Daridorexant

Category: sleep

Aliases: Quviviq

Pharmacological Mechanism

Dual orexin receptor antagonist; shorter half-life (~8h) than suvorexant or lemborexant — designed to minimize next-day residual sedation. FDA approved 2022 for chronic insomnia.

Half-Life (t½)

PO: 8h

Dosing Guidelines

• PO: Typical 50mg (Range: 25 - 50 mg)

Target Organ Systems

• nervous